Skip to main content
Top
Published in: Journal of General Internal Medicine 8/2007

01-08-2007 | Updates

Update in Addiction Medicine for the Generalist

Authors: Adam J. Gordon, MD, MPH, Lynn E. Sullivan, MD, Daniel P. Alford, MD, MPH, Julia H. Arnsten, MD, MPH, Marc N. Gourevitch, MD, MPH, Stefan G. Kertesz, MD, MSc, Hillary V. Kunins, MD, MPH, MS, Joseph O. Merrill, MD, Jeffrey H. Samet, MD, MA, MPH, David A. Fiellin, MD

Published in: Journal of General Internal Medicine | Issue 8/2007

Login to get access

Excerpt

Generalist physicians can play a critical role in identifying and treating patients with addictions to alcohol, nicotine, and/or other drugs of abuse. In the United States, nicotine dependence and unhealthy alcohol use are the first (18.1%) and third (3.5%) leading causes, respectively, of preventable deaths.1 Primary care physicians have not traditionally treated substance use despite the harmful effects that addiction can cause in their patients. The objective of this paper is to present recent evidence on recognizing and treating addiction disorders that is relevant for generalist physicians. We conducted an electronic database (PubMed) search to systematically identify recent (January 1, 2003, to June 1, 2006), human subject, English language, peer-reviewed, research articles or publications that impact generalist care for patients with addiction disorders. The search strategy and consensus deliberations were used to identify important articles in the categories of screening strategies for patients with alcohol problems and use of specific pharmacotherapies for patients with alcohol, nicotine, and opioid dependence. …
Literature
1.
go back to reference Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238–45.PubMedCrossRef Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238–45.PubMedCrossRef
2.
go back to reference Substance Abuse and Mental Health Services Administration Office of Applied Studies. Results from the 2004 Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2005. DHHS publication no. SMA 05-4062, NSDUH series H-28. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Results from the 2004 Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies; 2005. DHHS publication no. SMA 05-4062, NSDUH series H-28.
3.
go back to reference Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend. 2004;74(3):223–34.PubMedCrossRef Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend. 2004;74(3):223–34.PubMedCrossRef
5.
go back to reference Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(7):557–68.PubMed Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140(7):557–68.PubMed
6.
go back to reference Pettinati HM, Weiss RD, Miller WR, Donovan D, Denise B, Rounsaville BJ. COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004. DHHS publication no. (NIH) 04-5289. Pettinati HM, Weiss RD, Miller WR, Donovan D, Denise B, Rounsaville BJ. COMBINE Monograph Series, Volume 2. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004. DHHS publication no. (NIH) 04-5289.
7.
go back to reference Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA. 2006;295(17):2003–17.PubMedCrossRef Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA. 2006;295(17):2003–17.PubMedCrossRef
8.
go back to reference Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl. 2005;(15):170–8. Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol Suppl. 2005;(15):170–8.
9.
go back to reference Miller WR. Combined behavioral intervention manual. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004. NIH publication no. 04-5288. Miller WR. Combined behavioral intervention manual. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004. NIH publication no. 04-5288.
10.
go back to reference Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–25.PubMedCrossRef Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–25.PubMedCrossRef
11.
go back to reference Miller WR, Walters ST, Bennett ME. How effective is alcoholism treatment in the United States? J Stud Alcohol. 2001;62(2):211–20.PubMed Miller WR, Walters ST, Bennett ME. How effective is alcoholism treatment in the United States? J Stud Alcohol. 2001;62(2):211–20.PubMed
12.
go back to reference Tucker JA, Roth DL. Extending the evidence hierarchy to enhance evidence-based practice for substance use disorders. Addiction. 2006;101(7):918–32.PubMedCrossRef Tucker JA, Roth DL. Extending the evidence hierarchy to enhance evidence-based practice for substance use disorders. Addiction. 2006;101(7):918–32.PubMedCrossRef
14.
go back to reference McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635–45.PubMedCrossRef McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635–45.PubMedCrossRef
15.
go back to reference National Institute on Alcohol Abuse and Alcoholism. Helping Patients Who Drink Too Much: A Clinician’s Guide. Rockville, MD: U.S. Department of Health & Human Services; 2005. NIH publication no. 05-3769. National Institute on Alcohol Abuse and Alcoholism. Helping Patients Who Drink Too Much: A Clinician’s Guide. Rockville, MD: U.S. Department of Health & Human Services; 2005. NIH publication no. 05-3769.
16.
go back to reference Fleming MF. In search of the Holy Grail for the detection of hazardous drinking. J Fam Pract. 2001;50(4):321–2.PubMed Fleming MF. In search of the Holy Grail for the detection of hazardous drinking. J Fam Pract. 2001;50(4):321–2.PubMed
17.
go back to reference Gordon AJ, Maisto SA, McNeil M, et al. Three questions can detect hazardous drinkers. J Fam Pract. 2001;50(4):313–20.PubMed Gordon AJ, Maisto SA, McNeil M, et al. Three questions can detect hazardous drinkers. J Fam Pract. 2001;50(4):313–20.PubMed
18.
go back to reference Canagasaby A, Vinson DC. Screening for hazardous or harmful drinking using one or two quantity–frequency questions. Alcohol Alcohol. 2005;40(3):208–13.PubMed Canagasaby A, Vinson DC. Screening for hazardous or harmful drinking using one or two quantity–frequency questions. Alcohol Alcohol. 2005;40(3):208–13.PubMed
19.
go back to reference Williams R, Vinson DC. Validation of a single screening question for problem drinking. J Fam Pract. 2001;50(4):307–12.PubMed Williams R, Vinson DC. Validation of a single screening question for problem drinking. J Fam Pract. 2001;50(4):307–12.PubMed
20.
go back to reference Vinson DC. Screening question for alcohol abuse. Am Fam Physician. 2002;66(2):209.PubMed Vinson DC. Screening question for alcohol abuse. Am Fam Physician. 2002;66(2):209.PubMed
21.
go back to reference Taj N, Devera-Sales A, Vinson DC. Screening for problem drinking: does a single question work? J Fam Pract. 1998;46(4):328–35.PubMed Taj N, Devera-Sales A, Vinson DC. Screening for problem drinking: does a single question work? J Fam Pract. 1998;46(4):328–35.PubMed
23.
go back to reference Centers for Disease Control and Prevention. Smoking-attributable mortality and years of potential life lost—United States, 1984. MMWR Morb Mortal Wkly Rep. 1997;46(20):444–51. Centers for Disease Control and Prevention. Smoking-attributable mortality and years of potential life lost—United States, 1984. MMWR Morb Mortal Wkly Rep. 1997;46(20):444–51.
24.
go back to reference Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;(1):CD003041. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;(1):CD003041.
25.
go back to reference Friedenreich CM. Methods for pooled analyses of epidemiologic studies. Epidemiology. 1993;4(4):295–302.PubMedCrossRef Friedenreich CM. Methods for pooled analyses of epidemiologic studies. Epidemiology. 1993;4(4):295–302.PubMedCrossRef
26.
go back to reference Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.PubMedCrossRef Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84.PubMedCrossRef
27.
go back to reference Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef
28.
go back to reference National Cholesterol Education Program Expert Panel on Detection EaToHBCiAATPI. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421. National Cholesterol Education Program Expert Panel on Detection EaToHBCiAATPI. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
29.
go back to reference Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38.PubMedCrossRef Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38.PubMedCrossRef
30.
go back to reference Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39.PubMedCrossRef Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39.PubMedCrossRef
31.
go back to reference The Tobacco Use and Dependence Clinical Practice Guideline Panel SaCR. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA. 2000;283(24):3244–54.CrossRef The Tobacco Use and Dependence Clinical Practice Guideline Panel SaCR. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA. 2000;283(24):3244–54.CrossRef
32.
go back to reference Thorndike AN, Rigotti NA, Stafford RS, Singer DE. National patterns in the treatment of smokers by physicians. JAMA. 1998;279(8):604–8.PubMedCrossRef Thorndike AN, Rigotti NA, Stafford RS, Singer DE. National patterns in the treatment of smokers by physicians. JAMA. 1998;279(8):604–8.PubMedCrossRef
33.
go back to reference Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55.PubMedCrossRef Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55.PubMedCrossRef
34.
go back to reference Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56–63.PubMedCrossRef Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56–63.PubMedCrossRef
35.
go back to reference Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64–71.PubMedCrossRef Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64–71.PubMedCrossRef
36.
go back to reference Johnston LD, O’Malley PM, Backman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings. Bethesda, MD: National Institute on Drug Abuse; 2005. Johnston LD, O’Malley PM, Backman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings. Bethesda, MD: National Institute on Drug Abuse; 2005.
37.
go back to reference Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35(12):1747–59.PubMedCrossRef Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35(12):1747–59.PubMedCrossRef
38.
go back to reference Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manage. 2004;28(2):176–88.PubMedCrossRef Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manage. 2004;28(2):176–88.PubMedCrossRef
39.
go back to reference Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–76.PubMedCrossRef Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–76.PubMedCrossRef
40.
go back to reference Institute of Medicine. Improving the Quality of Healthcare for Mental and Substance-use Conditions: The Quality Chasm Series. Washington, DC: The National Academies Press; 2005. Institute of Medicine. Improving the Quality of Healthcare for Mental and Substance-use Conditions: The Quality Chasm Series. Washington, DC: The National Academies Press; 2005.
41.
go back to reference Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: The National Academies Press; 2001. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: The National Academies Press; 2001.
Metadata
Title
Update in Addiction Medicine for the Generalist
Authors
Adam J. Gordon, MD, MPH
Lynn E. Sullivan, MD
Daniel P. Alford, MD, MPH
Julia H. Arnsten, MD, MPH
Marc N. Gourevitch, MD, MPH
Stefan G. Kertesz, MD, MSc
Hillary V. Kunins, MD, MPH, MS
Joseph O. Merrill, MD
Jeffrey H. Samet, MD, MA, MPH
David A. Fiellin, MD
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 8/2007
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-007-0133-4

Other articles of this Issue 8/2007

Journal of General Internal Medicine 8/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.